drugset / Trial / NCT02117219
Phase 1 Study to Evaluate MEDI4736 in Subjects With Myelodysplastic Syndrome
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a multicenter, open-label, Phase 1 study to assess the safety and antitumor activity of MEDI4736 as Monotherapy or in Combination with Tremelimumab with or without Azacitidine in Subjects with myelodysplastic syndrome after treatment with hypomethylating agents
Timeline
- Start
- 2014-05-20
- Primary completion
- 2019-04-30
- Completion
- 2019-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | — | Subcutaneous |
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Tremelimumab | Monoclonal antibody | — | Intravenous |